2MD, a new anabolic agent for osteoporosis treatment

Osteoporosis International

Volumn 17, Issue 5, 2006, Pages 704-715

  Plum, L A ^a   Fitzpatrick, L A ^b   Ma, X ^a   Binkley, N C ^c   Zella, J B ^a   Clagett Dame, M ^a   DeLuca, H F ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Bone; Osteoporosis; Rat; Therapy; Vitamin D analog

Indexed keywords

2 METHYLENE 19 NOR 1ALPHA,25 DIHYDROXYVITAMIN D3; ANABOLIC AGENT; CALCITRIOL; CALCITRIOL DERIVATIVE; UNCLASSIFIED DRUG;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BODY WEIGHT; BONE MASS; CANCELLOUS BONE; CONTROLLED STUDY; CORTICAL BONE; DIET SUPPLEMENTATION; DRUG DOSE REGIMEN; DRUG EFFECT; FEMALE; HISTOLOGY; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RAT; TRABECULAR BONE;

ANABOLIC AGENTS; ANALYSIS OF VARIANCE; ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CALCITRIOL; CALCIUM; FEMALE; OSTEOGENESIS; OSTEOPOROSIS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33645755226     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-005-0036-3     Document Type: Article

References (33)

1. US Department of Health and Human Services (2004) Bone health and osteoporosis: a report of the surgeon general. Rockville, MD
2. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitla BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
3. Deal C, Gideon J (2003) Recombinant human PTH 1-34 (Forteo): an anabolic drug for osteoporosis. Cleveland Clin J Med 70:585-601
4. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Dannata J, Falogh A, Lemmel E-M, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster J-Y (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-468
5. 3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues. J Med Chem 41:4662-4674
6. 3 selectively induces bone formation. Proc Natl Acad Sci USA 99:13487-13491
7. Yasuda H, Shima N, Nakagawa N, Yamagushi K, Kinosaki M, Mochizuka S-I, Tomoyasu A, Yano K, Gotto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602
8. Suda T, DeLuca HF, Tanaka Y (1970) Biological activity of 25-hydroxyergocalciferol in rats. J Nutr 100:1049-1052
9. Haffa A, Krueger D, Bruner J, Engelke J, Gundberg C, Akhter M, Binkley N (2000) Diet- or warfarin-induced vitamin K insufficiency elevates circulating undercarboxylated osteocalcin without altering skeletal status in growing female rats. J Bone Miner Res 15:872-878
10. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier P, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595-610
11. Westerlind KC, Gibson KJ, Malone P, Evans GL, Turner RT (1998) Differential effects of estrogen metabolites on bone and reproductive tissues of ovariectomized rats. J Bone Miner Res 13:1023-1031
12. Simone WS, Lacey DL, Dunstan CR, Kelley M, Chang M-S, Lüthy R, Nguyen HQ, Wooden S, Bennett L et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
13. Sibonga JD, Zhang M, Ritman EL, Turner RT (2000) Restoration of bone mass in the severely osteopenic senescent rat. J Gerontol Biol Sci 55A:B71-B78
14. Markose ER, Stein JL, Stein GS, Lian JB (1990) Vitamin D-mediated modifications in protein-DNA interactions at two promoter elements of the osteocalcin gene. Proc Natl Acad Sci USA 87:1701-1705
15. Okazaki T, Zajac JD, Igarashi T, Ogata E, Kronenberg HM (1991) Negative regulatory elements in the human parathyroid hormone gene. J Biol Chem 266:21903-21910
16. Fraser DR, Kodicek E (1970) Unique biosynthesis by kidney of a biologically active vitamin D metabolite. Nature 228:764-766
17. Holick MF, Schnoes HK, DeLuca HF, Suda T, Cousins RJ (1971) Isolation and identification of 1,25-dihydroxycholecalciferol. A metabolite of vitamin D active in intestine. Biochemistry 10:2799-2804
18. Kleerekoper M, Frame B, Villanueva AR, Oliver I, Rao DS, Matkovic V, Parfitt AM, Chir B (1981) Treatment of osteoporosis with sodium fluoride alternating with calcium and vitamin D. In: DeLuca HF, Frost HM, Jee WSS, Johnson CC, Parfitt AM (eds) Osteoporosis: recent advances in pathogenesis and treatment. University Park Press, Baltimore,pp 441-448
19. 3 on calcium balance and bone turnover and its effect on vertebral fracture rate. Metabolism 39:30-34
20. Aloia JF, Vaswani A, Yeh JK, Ellis K. Yasumura S, Cohn SH (1988) Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med 84:401-408
21. Dambacher MA, Kranich M, Schacht E, Neff M (1997) Can the fast bone loss in osteoporotic and osteopenic patients be stopped with active vitamin D metabolites? Calcif Tissue Int 60:115-118
22. Ott SM, Chesnut CH III (1989) Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Int Med 110:267-274
23. Caniggia A, Nuti R, Lore F, Martini G, Turchetti V, Righi G (1990) Long-term treatment with calcitriol in postmenopausal osteoporosis. Metabolism 39:43-49
24. Tilyard MW, Spears GFS, Thomson J, Dovey S (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326:357-362
25. 3. Bone Miner 3:47-52
26. 3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 54:370-376
27. 3. J Bone Miner Metab 10:184-188
28. Riggs BL, Nelson KI (1985) Effect of long term treatment with calcitriol on calcium absorption and mineral metabolism in postmenopausal osteoporosis. J Clin Endocrinol Metab 61:457-461
29. 2 supplementation on calcium absorption in elderly women with vertebral fractures. Osteoporos Int 6:284-290
30. Need AG, Morris HA, Horowitz M, Nordin BEC (1997) The response to calcitriol therapy in postmenopausal osteoporotic women is a function of initial calcium absorptive status. Calcif Tissue Int 61:6-9
31. Gallagher JC, Goldgar D (1990) Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Int Med 113:649-655
32. 3 hormone analogues and a LXXLL-containing coactivator peptide. Biochemistry 43:4101-4110
33. 3 potently stimulates gene-specific DNA binding of the vitamin D receptor in osteoblasts. J Biol Chem 278:31756-31765